Lesson plan
Pynegabine
Pynegabine (developmental code name HN37) is a K v 7.2 and K v 7.3 potassium channel opener which is under development for the treatment of epilepsy in China. The drug is an analogue of flupirtine and retigabine (ezogabine). However, it shows 55-fold greater potency in activating K v 7.2 channels and 127-fold greater potency in activating K v 7.3 channels compared to retigabine in vitro. In addition, it shows improved chemical or metabolic stability compared to retigabine and in relation to this may have reduced toxicity in comparison. The drug is under development by the Shanghai Institute of Materia Medica and Hainan Haiyao. As of 2026, it is in phase 2 clinical trials for epilepsy.
Article summary
Pynegabine (developmental code name HN37) is a K v 7.2 and K v 7.3 potassium channel opener which is under development for the treatment of epilepsy in China. The drug is an analogue of flupirtine and retigabine (ezogabine). However, it shows 55-fold greater potency in activating K v 7.2 channels and 127-fold greater potency in activating K v 7.3 channels compared to retigabine in vitro. In addition, it shows improved chemical or metabolic stability compared to retigabine and in relation to this may have reduced toxicity in comparison. The drug is under development by the Shanghai Institute of Materia Medica and Hainan Haiyao. As of 2026, it is in phase 2 clinical trials for epilepsy.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.